More importantly, AML patients with higher FOXP3 and PD-1 co-expression had worse OS (PD-1highFOXP3high vs. PD-1lowFOXP3low, 24-month OS: 35% vs 65%, P = 0.018) (Figure 1D). The gene discussed is FOXP3; the disease is acute myeloid leukemia.